International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025
The impact of low-dose aspirin on hemoglobin levels in pregnancy: A secondary analysis of a randomized controlled trial for prevention of hypertensive disorders of pregnancy.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ngcobo N M, Dorsamy V, Bagwandeen C, Mkhize P Z, Moodley J
Аннотация
OBJECTIVES: This study evaluates the association of low-dose aspirin (LDA) with hemoglobin (Hb) levels during pregnancy and explores how changes in Hb levels relate to hypertensive disorders of pregnancy (HDP).
METHODS: This secondary analysis of a randomized controlled trial comprised 249 pregnant women recruited from a regional hospital in Durban, South Africa (SA). Participants were randomized to receive either 162 mg of LDA daily (intervention) or standard care (control). Hemoglobin levels were measured at enrolment and again at birth. Data on maternal outcomes, including HDP, were analyzed in relation to changes in Hb levels to assess potential associations.
RESULTS: At enrolment, the predominant Hb range was 9.0-10.9 g/dL (mild anemia) in 51.4% of participants, with comparable Hb distributions between groups. By birth, 43.4% remained mildly anemic, while 44.2% had normal Hb levels (11-13 g/dL). Among participants who experienced a decline in Hb, the reduction was significantly mitigated in the intervention compared to the control group (ΔHb = -0.902 vs. -1.422, P = 0.002, η2 = 0.088). Declining Hb levels increase the odds of developing HDP compared to increasing Hb (odds ratio = 2.29 vs. 0.44, P = 0.032). However, the intervention group within this subgroup had 76% reduction in risk of developing HDP (RR = 0.24, 95% confidence interval [0.11-0.53], P < 0.001) compared to the control group.
CONCLUSION: Low-dose aspirin was associated with a smaller decline in Hb levels and lower HDP risk; consistent with a potential hematological benefit beyond preeclampsia prevention, although this represents an association rather than causation. Hemoglobin reduction might also serve as an early predictor of HDP.
METHODS: This secondary analysis of a randomized controlled trial comprised 249 pregnant women recruited from a regional hospital in Durban, South Africa (SA). Participants were randomized to receive either 162 mg of LDA daily (intervention) or standard care (control). Hemoglobin levels were measured at enrolment and again at birth. Data on maternal outcomes, including HDP, were analyzed in relation to changes in Hb levels to assess potential associations.
RESULTS: At enrolment, the predominant Hb range was 9.0-10.9 g/dL (mild anemia) in 51.4% of participants, with comparable Hb distributions between groups. By birth, 43.4% remained mildly anemic, while 44.2% had normal Hb levels (11-13 g/dL). Among participants who experienced a decline in Hb, the reduction was significantly mitigated in the intervention compared to the control group (ΔHb = -0.902 vs. -1.422, P = 0.002, η2 = 0.088). Declining Hb levels increase the odds of developing HDP compared to increasing Hb (odds ratio = 2.29 vs. 0.44, P = 0.032). However, the intervention group within this subgroup had 76% reduction in risk of developing HDP (RR = 0.24, 95% confidence interval [0.11-0.53], P < 0.001) compared to the control group.
CONCLUSION: Low-dose aspirin was associated with a smaller decline in Hb levels and lower HDP risk; consistent with a potential hematological benefit beyond preeclampsia prevention, although this represents an association rather than causation. Hemoglobin reduction might also serve as an early predictor of HDP.